Quantcast

Latest Tyrosine kinases Stories

2014-08-27 08:27:31

SAN DIEGO, Aug. 27, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Baird 2014 Health Care Conference to be held at The New York Palace Hotel in New York City on September 3-4, 2014. Alan Fuhrman, Ambit's CFO, will provide an overview of the Company and its lead drug candidate,...

2014-04-09 09:57:59

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia. Results of the research by Johns Hopkins Kimmel Cancer Center investigators, described March 6 in the journal Blood, show that two doses a day of TTT-3002 eliminated leukemia cells in a group of mice within 10 days. The treatment performed as well...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related